Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma

Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma

Background Melanoma is an immune sensitive disease, as demonstrated by the activity of immune check point blockade (ICB), but many patients will either not respond or relapse. More recently, tumor infiltrating lymphocyte (TIL) therapy has shown promising efficacy in melanoma treatment after ICB fail...

Full description

Bibliographic Details
Main Authors: Christian Klein, Daria Briukhovetska, Michael von Bergwelt-Baildon, Sebastian Kobold, Mitchell P Levesque, Bruno L Cadilha, Stefan Endres, Mohamed-Reda Benmebarek, Hannah Obeck, Sophia Stock, Florian Märkl, Julius Keyl, Martina Geiger, Clara Karches, Melanie Schwerdtfeger, Stefanos Michaelides, Jakob Jobst, Philipp Jie Müller, Lina Majed, Matthias Seifert, Anna-Kristina Klüver, Theo Lorenzini, Ruth Grünmeier, Moritz Thomas, Adrian Gottschlich, Richard Klaus, Carsten Marr, Simon Rothenfusser, Markus Vincent Heppt
Format: Article
Language:English
Published: BMJ Publishing Group 2023-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/5/e006436.full

Internet

https://jitc.bmj.com/content/11/5/e006436.full

Similar Items